Want to see SRPT full AI Analyst Report?
SRPT Stock Chart & Stats
$18.92
-$0.20(-1.26%)
At close: 4:00 PM EDT
$18.92
-$0.20(-1.26%)
Day’s Range― - ―
52-Week Range$14.68 - $25.32
Previous CloseN/A
Volume2.14M
Average Volume (3M)3.05M
Market Cap
$2.45B
Enterprise Value$2.15K
Total Cash (Recent Filing)$788.49M
Total Debt (Recent Filing)$1.05B
Price to Earnings (P/E)―
Beta1.32
Next Earnings
Nov 04, 2026EPS Estimate
0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.44
Shares Outstanding105,627,020
10 Day Avg. Volume3,169,295
30 Day Avg. Volume3,051,246
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.98
Price to Sales (P/S)1.03
P/FCF Ratio-7.33
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$22.88Price Target Upside20.90% Upside
Rating ConsensusHold
Number of Analyst Covering17
EPS Forecast (FY)3.19
Revenue Forecast (FY)$1.84B
Bulls Say, Bears Say
Bulls Say
Durable PMO Franchise And MarginsStable PMO demand, high patient adherence and strong gross margins provide a durable commercial foundation. This recurring franchise can support cash generation while newer gene and RNA therapies develop.
Pipeline Breadth And Regulatory ProgressAccepted regulatory filings and progress in siRNA expand Sarepta’s potential beyond its current products. A broader precision-medicine pipeline can diversify revenue and extend the company’s rare-disease platform.
Operating Discipline And ProfitabilityDeep expense reductions alongside operating profitability show improved cost control and operating leverage. Sustaining this discipline could help Sarepta convert its commercial scale and collaboration revenue into more consistent earnings.
Bears Say
Product Revenue ContractionThe revenue decline indicates that Sarepta’s near-term growth is vulnerable to weaker ELEVIDYS demand despite its established PMO franchise. Continued contraction would pressure operating leverage and delay progress toward durable profitability.
Persistent Cash BurnNegative operating and free cash flow show that the business has not yet demonstrated self-funding operations. Continued investment, manufacturing needs or setbacks could require additional financing and weaken financial flexibility.
Regulatory, Safety And Competitive ExposureDelayed safety data and the LGMD clinical hold restrict pipeline execution and postpone potential label expansion. Competition in exon skipping could also pressure PMO adoption, pricing or market share over the medium term.
Sarepta Therapeutics News
SRPT FAQ
What was Sarepta Therapeutics’s price range in the past 12 months?
Sarepta Therapeutics lowest stock price was $14.68 and its highest was $25.32 in the past 12 months.
What is Sarepta Therapeutics’s market cap?
Sarepta Therapeutics’s market cap is $2.45B.
When is Sarepta Therapeutics’s upcoming earnings report date?
Sarepta Therapeutics’s upcoming earnings report date is Nov 04, 2026 which is in 60 days.
How were Sarepta Therapeutics’s earnings last quarter?
Sarepta Therapeutics released its earnings results on Aug 05, 2026. The company reported -$0.05 earnings per share for the quarter, missing the consensus estimate of $0.217 by -$0.267.
Is Sarepta Therapeutics overvalued?
According to Wall Street analysts Sarepta Therapeutics’s price is currently Undervalued.
Does Sarepta Therapeutics pay dividends?
Sarepta Therapeutics does not currently pay dividends.
What is Sarepta Therapeutics’s EPS estimate?
Sarepta Therapeutics’s EPS estimate is 0.17.
How many shares outstanding does Sarepta Therapeutics have?
Sarepta Therapeutics has 105,627,020 shares outstanding.
What happened to Sarepta Therapeutics’s price movement after its last earnings report?
Sarepta Therapeutics reported an EPS of -$0.05 in its last earnings report, missing expectations of $0.217. Following the earnings report the stock price went up 5.336%.
Which hedge fund is a major shareholder of Sarepta Therapeutics?
Currently, no hedge funds are holding shares in SRPT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sarepta Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$22.88 (20.90% Upside)
$22.88 (20.90% Upside)
Blogger Sentiment
Bullish
SRPT Sentiment 68%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 4.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 8.3%
Last 30 Days ▼ 8.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.31%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-13.35%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Sarepta Therapeutics
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.
SRPT Company Deck
SRPT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced picture: Sarepta demonstrated strong operational discipline (GAAP and non-GAAP profitability), meaningful cash growth, expense reductions, and progress across its siRNA and regulatory programs — all positive signs. However, a substantial year-over-year revenue decline (34% in Q2) driven by lower ELEVIDYS demand, near-term expectations for modestly lower product revenue in H2, a $39M litigation charge, and timing delays for key safety readouts temper the outlook. Pipeline catalysts and accepted sNDAs provide upside potential, but near-term top-line pressure and regulatory/timing uncertainties leave the narrative mixed.View all SRPT earnings summariesSRPT Stock 12 Month Forecast
Average Price Target
$22.88
▲(20.90% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
uniQure
―
Wave Life Sciences
―
Solid Biosciences
―
Taysha Gene Therapies
―
Ownership Overview
6.16% Insiders
16.96% Mutual Funds
11.23% Other Institutional Investors
28.80% Public Companies and
Individual Investors